Transcat (NASDAQ:TRNS) Cut to Market Perform at Northland Securities

Northland Securities lowered shares of Transcat (NASDAQ:TRNS) from an outperform rating to a market perform rating in a report released on Wednesday morning, MarketBeat Ratings reports. Northland Securities currently has $95.00 target price on the scientific and technical instruments company’s stock. Northland Securities also issued estimates for Transcat’s Q2 2027 earnings at $0.41 EPS, Q3 2027 earnings at $0.20 EPS, Q4 2027 earnings at $0.60 EPS, FY2027 earnings at $1.71 EPS, FY2028 earnings at $2.12 EPS, FY2029 earnings at $2.58 EPS, FY2030 earnings at $3.01 EPS and FY2031 earnings at $3.53 EPS.

TRNS has been the topic of a number of other reports. Wall Street Zen raised shares of Transcat from a “sell” rating to a “hold” rating in a research report on Sunday, June 28th. Weiss Ratings raised Transcat from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, May 28th. Finally, Zacks Research upgraded shares of Transcat from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Transcat presently has an average rating of “Hold” and an average target price of $105.50.

Transcat Stock Performance

TRNS stock opened at $93.11 on Wednesday. Transcat has a twelve month low of $50.23 and a twelve month high of $96.60. The company has a quick ratio of 1.99, a current ratio of 2.49 and a debt-to-equity ratio of 0.36. The company has a market cap of $871.51 million, a P/E ratio of 251.65 and a beta of 0.68. The business’s fifty day moving average is $89.60 and its 200-day moving average is $79.61.

Transcat (NASDAQ:TRNS) last announced its quarterly earnings data on Tuesday, August 4th. The scientific and technical instruments company reported $0.51 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.13. The business had revenue of $92.95 million during the quarter, compared to analysts’ expectations of $86.55 million. Transcat had a return on equity of 5.56% and a net margin of 0.99%. Equities research analysts forecast that Transcat will post 1.74 EPS for the current year.

Institutional Investors Weigh In On Transcat

A number of institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. bought a new position in Transcat during the second quarter worth about $67,445,000. Vanguard Group Inc. lifted its position in shares of Transcat by 0.4% in the third quarter. Vanguard Group Inc. now owns 530,771 shares of the scientific and technical instruments company’s stock valued at $38,852,000 after buying an additional 2,041 shares during the last quarter. Royce & Associates LP boosted its stake in shares of Transcat by 15.3% during the 4th quarter. Royce & Associates LP now owns 390,546 shares of the scientific and technical instruments company’s stock worth $22,156,000 after acquiring an additional 51,774 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of Transcat by 3.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 262,033 shares of the scientific and technical instruments company’s stock worth $19,244,000 after acquiring an additional 9,266 shares during the last quarter. Finally, Wellington Management Group LLP raised its stake in Transcat by 677.7% in the 4th quarter. Wellington Management Group LLP now owns 248,539 shares of the scientific and technical instruments company’s stock valued at $14,100,000 after acquiring an additional 216,579 shares during the period. 98.34% of the stock is owned by institutional investors.

Key Stories Impacting Transcat

Here are the key news stories impacting Transcat this week:

• Positive Sentiment: Transcat’s latest quarterly results exceeded expectations, with earnings of $0.51 per share versus the $0.38 consensus estimate and revenue of $92.95 million compared with expectations of $86.55 million. This indicates solid operating momentum, although the results are not the primary focus of today’s trading. TRNS Q2 deep dive: Service segment drives growth, margin pressures persist
• Neutral Sentiment: Northland’s $95 price target and “Market Perform” rating indicate a neutral stance rather than a bullish or bearish recommendation. Transcat Rating Lowered to Market Perform at Northland Securities
• Negative Sentiment: Northland cut its Q3 2027 EPS forecast to $0.20 from $0.38 and lowered FY2027 EPS to $1.71 from $1.86. It also reduced estimates for FY2028 to $2.12 from $2.33, FY2029 to $2.58 from $3.18, and FY2030 to $3.01 from $3.51.
• Negative Sentiment: The firm additionally lowered Q2 2027 EPS to $0.41 from $0.45, Q4 2027 EPS to $0.60 from $0.62, and FY2031 EPS to $3.53 from $3.88. The broad-based reductions imply weaker-than-previously-expected earnings growth and are likely weighing on the stock.
• Negative Sentiment: Transcat trades at a very elevated valuation, with a trailing P/E above 250. Downward revisions therefore create greater downside sensitivity, particularly while the stock is near its 52-week high.

Transcat Company Profile

Transcat, Inc (NASDAQ: TRNS) is a leading provider of calibration, laboratory, and metrology services in North America. Founded in 1964 and headquartered in Ronkonkoma, New York, the company specializes in ensuring the accuracy and compliance of measurement instruments across a wide range of industries. Transcat operates a network of ISO/IEC 17025–accredited laboratories and offers on-site field calibration, instrument repair, and preventive maintenance services.

In addition to its calibration services, Transcat distributes precision instrumentation and related software solutions from top manufacturers.